iCo Therapeutics is a "Search and Development" company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development of these therapeutics may include drug delivery technologies-such as sustained release or biodegradable matrices to extend patent coverage.
There is a significant decrease in development risk associated with targeting existing drugs, including:
Chief Financial Officer